Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Custom

Click to order products ascending

Display 15 Products per page

Xofigo
Read More
Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases.
January 18, 2018
Find out more
Xolair
Read More
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma.
February 16, 2018
Find out more
Xtandi
Read More
Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits binding of the androgens to the AR, inhibits AR nuclear translocation, and inhibits association of the AR with DNA.
January 18, 2018
Find out more
Xultophy
Read More
Xultophy ([insulin degludec + liraglutide]; Novo Nordisk) is a once-daily, injectable combination product comprising a fixed ratio of Novo Nordisk’s long-lasting basal insulin Tresiba (insulin degludec) and glucagon-like peptide-1 receptor agonist Victoza (liraglutide) for the treatment of type 2 diabetes.
November 7, 2017
Find out more
Xyntha
Read More
Xyntha is a recombinant factor VIII (rfVIII) therapy approved for the treatment of hemophilia A.

Although Pfizer has taken steps to enhance the product by improving the manufacturing processes

and developing an application device for the therapy, Xyntha’s target patient population will be

reduced by competitor therapies approved for prophylactic use.
May 4, 2018
Find out more
Yervoy
Read More
Yervoy (ipilimumab; Bristol-Myers Squibb/Ono Pharmaceutical) is an intravenous fully humanized immunoglobulin-G1 monoclonal antibody that targets human cytotoxic T-lymphocyte-associated protein-4 (CTLA-4).
May 23, 2018
Find out more
Yescarta
Read More
Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.
January 30, 2019
Find out more
Ygalo
Read More
Ygalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine
August 9, 2018
Find out more
Yonsa
Read More
Yonsa (Churchill Pharmaceuticals) is an oral, ultramicrosize tablet formulation of abiraterone acetate that inhibits 17 alpha-hydroxylase (CYP17). The CYP17 family of enzymes catalyze the hydroxylation of intermediates involved in testosterone synthesis, a common driver of prostate cancer genesis and recurrence.
January 18, 2018
Find out more
Zafatek
Read More
Zafatek (trelagliptin; Takeda) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.
November 7, 2017
Find out more
Zaltrap
Read More
Zaltrap is a human recombinant fusion protein comprising segments of the human VEGFRs 1 and 2
and the Fc portion of the human immunoglobulin G1 (Tang et al., 2008).
January 19, 2016
Find out more
Zanubrutinib
Read More
Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson & Johnson). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.
January 31, 2019
Find out more
Zeftera
Read More
Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin.
June 19, 2015
Find out more
Zejula
Read More
Zejula (niraprib; Tesaro/Takeda) is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.
August 17, 2017
Find out more
Zelapar
Read More
Zelapar (selegiline; Valeant) is a novel rapidly disintegrating tablet formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline.
October 24, 2014
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *